Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESOLVE: Pembrolizumab in Post-molar GTN
NCT05635344Phase 2Recruiting
- Sponsor
- Imperial College London
- Start
- Feb 2024
- Primary completion
- Feb 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in gestational trophoblastic neoplasia (GTN), sponsored by Imperial College London. Started Feb 2024; status: recruiting.
02
Drugs
03
Conditions
gestational trophoblastic neoplasia (GTN)
Beyond the preview
Go deeper on NCT05635344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05635344.